0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessIn this study, data available at the time of FDA drug approval indicated that novel cancer therapies were associated with substantial tumor responses but with prolonging median overall survival by only 2.40 months. Approval data from 17 years of clinical trials suggested that patients and clinicians typically had limited information available regarding the benefits of novel cancer treatments at market entry.
Aviv Ladanie, Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal, Tiago Pereira, Francesco Sclafani, Amanda K. Herbrand, Matthias Briel, Juan Martín-Liberal, Thomas Schmid, Hannah Ewald, John P A Ioannidis, Heiner C. Bucher, Benjamin Kasenda, Lars G. Hemkens (2020). Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. , 3(11), DOI: https://doi.org/10.1001/jamanetworkopen.2020.24406.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2020
Authors
16
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1001/jamanetworkopen.2020.24406
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
